Drug firm Ranbaxy Laboratories on Friday said Luxembourg Stock Exchange (LSE) will delist the company's Global Depository Receipts programme with effect from December 15.
Drug firm Ranbaxy Laboratories on Friday said Luxembourg Stock Exchange (LSE) will delist the company's Global Depository Receipts programme with effect from December 15.
In view of the proposed termination of the deposit agreement on December 15, 2014, the LSE will de-list the GDS from the official list and withdraw the trading of GDS on the Euro MTF Market of the LSE with effect from December 15, 2014, Ranbaxy Laboratories said in a filing to the BSE.
The company said it has received a letter from LSE in this regard.
Earlier this month, the company had said that it has notified the Bank of New York Mellon to terminate the Deposit Agreements dated July 7, 1994 and underlying Global Depository
Receipts (GDR) programme.
Ranbaxy shares on Friday closed at Rs 632.10 apiece on the BSE, up 1.34 percent from their previous close.
Ranbaxy Labs stock price
On October 31, 2014, Ranbaxy Laboratories closed at Rs 632.10, up Rs 8.35, or 1.34 percent. The 52-week high of the share was Rs 667.30 and the 52-week low was Rs 306.05.
The company's trailing 12-month (TTM) EPS was at Rs 20.93 per share as per the quarter ended September 2014. The stock's price-to-earnings (P/E) ratio was 30.2. The latest book value of the company is Rs 25.84 per share. At current value, the price-to-book value of the company is 24.46.
Anda sedang membaca artikel tentang
LSE to delist Ranbaxy GDR programme with effect from Dec 15
Dengan url
https://kesehatanda.blogspot.com/2014/11/lse-to-delist-ranbaxy-gdr-programme.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
LSE to delist Ranbaxy GDR programme with effect from Dec 15
namun jangan lupa untuk meletakkan link
LSE to delist Ranbaxy GDR programme with effect from Dec 15
sebagai sumbernya
0 komentar:
Posting Komentar